Berlin — Bayer CEO Werner Baumann said the company is "fully committed" to integrating recent acquisition Monsanto, despite a $289m jury award and a rising wave of lawsuits seeking to link its weed-killer Roundup with cancer. There is "an awful lot of excitement and enthusiasm" at Bayer about the $66bn Monsanto purchase, Baumann said on a conference call on Thursday. He reiterated that the company believes the jury decision is "wrong" and "inconsistent with the robust science-based conclusions of regulators and health authorities worldwide". "Nothing has changed concerning our strategy, attractive synergy potential and longer-term growth and margin expectations for our combined crop-science business," Baumann said. "We are very optimistic." Some 8,000 lawsuits had been filed over glyphosate, the main ingredient in Roundup, as of the end of July, Bayer said on Thursday. That compares to the 5,200 complaints previously disclosed, and the number will almost certainly keep climbing afte...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now